{"a":[{"_":"ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM","$":{"href":"/pharma/esc-az-ionis-wainua-post-mortem-throws-water-silencer-plus-stabilizer-approach-attr-cm","hreflang":"en"}}]}
Phase 3negativeWainuaNegative
AI Analysis
Summary
AstraZeneca and Ionis' phase 3 trial of Wainua, an antisense oligonucleotide for transthyretin-mediated amyloid cardiomyopathy, unexpectedly failed. The failure raises concerns about the viability of the silencer-plus-stabilizer approach for treating ATTR-CM.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Surprise washout in recent phase 3 trial; trial miss attributed to silencer-plus-stabilizer approach in ATTR-CM
Importance:8/10
Sentiment:
-0.90
Phase 3 failureantisense oligonucleotideATTR-CMsilencer drugdrug development
Read the original article
Published by FiercePharma on August 29, 2026 12:18 PM